Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12314900 | 1.00 | OPRM1 (0.44) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL14227389 | 0.93 | GRB2 (0.50) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL16338735 | 0.93 | OPRM1 (0.47) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL13084631 | 0.93 | GRB2 (0.50) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL12899266 | 0.93 | GRB2 (0.50) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL12261069 | 0.93 | GRB2 (0.50) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL12237919 | 0.93 | GRB2 (0.50) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL12237990 | 0.93 | OPRM1 (0.47) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL16350326 | 0.91 | OPRM1 (0.43) | OPRM1OPRK1GRB2CXCR4CAPN1 | |
| SCHEMBL1247799 | 0.90 | OPRM1 (0.48) | OPRM1OPRK1GRB2CXCR4NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |
| US-7820621-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2010-10-26 | — | — | US | disclosed |